Small-Cap Biotech Watchlist: Takeaways for Investors
January 20, 2017 Why should investors keep an eye on these twenty small-cap biotechs in 2017? The analysts who made the selections for The Life Sciences Report's 2017 Small-Cap Biotech Watchlist laid out their rationales at the Watchlist's launch at the Biotech Showcase in San Francisco on Jan. 11. In a panel discussion moderated by Maxim Group's senior managing director and the head of healthcare research Jason Kolbert, Raghuram "Ram" Selvaraju of Rodman & Renshaw; George Zavoico, senior equity analyst at JonesTrading Institutional Services; and Mike King, managing director and senior biotechnology analyst at JMP Securities, detailed their investment theses for the companies that made the cut.
from Biotech News